Why Johnson & Johnson Is a Stock You Can Own Forever
Most investors trade in and out of healthcare stocks chasing quarterly catalysts, but a small group of retirement portfolios quietly compound decade after decade on a single holding built to survive patent cliffs, market crashes, and pricing wars simultaneously.
Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) is a stock built to be owned for decades, not traded, because its combination of an AAA-tier balance sheet, a 64-consecutive year dividend growth streak and a diversified healthcare franchise across pharmaceuticals and medical devices is engineered to compound quietly through every market cycle.
Johnson & Johnson is the kind of holding a retirement-focused investor can own and stop watching.
Pillar One: Durability of the Business
JNJ operates across six priority areas: Oncology, Immunology, Neuroscience, Cardiovascular, Surgery, and Vision. Q1 2026 revenue reached $24.06 billion, up 9.9% year over year, with Innovative Medicine growing 11.2% and MedTech up 7.7%. Oncology drugs like DARZALEX ($3.96 billion, +22.5%) and TREMFYA (+68.3%) more than absorbed the 59.7% decline in STELARA from biosimilar competition. When your growth engines can eat a patent cliff and still deliver four consecutive EPS beats, the franchise is doing what a forever holding is supposed to do.
Pillar Two: Income Generation
The board raised the quarterly dividend 3.1% to $1.34 per share in April 2026, extending the streak to 64 consecutive years. That places JNJ in the highest tier of Dividend Kings. The company generated $19.7 billion in free cash flow during full-year 2025, more than enough to fund the payout, buybacks, and pipeline investment simultaneously. For income investors looking at multi-decade holdings, the 24/7 Wall St. research team recently outlined the framework in its Never Touch the Principal report on forever dividend positions.
Pillar Three: Surviving the Cycles
JNJ carries a beta of 0.235, meaning it moves a fraction of what the broader market does. Institutional ownership sits at 76.82%, and management raised full-year 2026 guidance to $100.3 billion to $101.3 billion in revenue with adjusted EPS of $11.45 to $11.65. Geographic balance ($13.33 billion U.S. and $10.73 billion Rest of World) further insulates the business from any single market shock.
Why JNJ Beats the Obvious Alternative
The natural comparison is AbbVie (NYSE:ABBV), often paired with JNJ in dividend portfolios. AbbVie only began its independent dividend history after its 2013 spin-off from Abbott, a fraction of JNJ’s 64-year streak, and its post-Humira revenue base remains heavily dependent on Skyrizi and Rinvoq to replace a single lost blockbuster. JNJ’s revenue is spread across dozens of products spanning drugs and devices. Through the next several market cycles, patent expirations, and pricing regimes, the more diversified balance sheet is the safer permanent holding.
The Underperformance Scenario
In risk-on, speculative growth markets, JNJ lags. A beta of 0.235 means it will not keep pace with high-beta names during a melt-up, and Q1 2026 included $330 million in litigation charges. That does not change the forever thesis. The right reason to own JNJ is to still be collecting a rising dividend in 2046, not to chase leadership in a bull run.
This is a long-term hold.
Contact [email protected] for any questions or corrections.
Joel South covers large-cap stocks, dividend investing, and major market trends, with a focus on earnings analysis, valuation, and turning complex data into actionable insights for investors.
He brings more than 15 years of experience as an investor and financial journalist, including 12 years at The Motley Fool, where he served as an investment analyst, Bureau Chief, and later led the Fool.com investing news desk. He has also co-hosted an investing podcast and appeared across TV and radio discussing market trends.
